Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies by Nemes, Zoltán et al.
 1
TRANSGLUTAMINASE-MEDIATED INTRAMOLECULAR CROSS-LINKING OF 
MEMBRANE-BOUND α-SYNUCLEIN  
PROMOTES AMYLOID FORMATION IN LEWY BODIES* 
Zoltán Nemes1, Goran Petrovski2, Maarten Aerts3, Kjell Seargent3, Bart Devreese3  
and László Fésüs2 
From Departments of Psychiatry1 and Biochemistry and Molecular Biology2 and Signaling and Apoptosis 
Research Group, Hungarian Academy of Sciences, Research Center for Molecular Medicine, University 
of Debrecen, Debrecen, Hungary H-4012, Laboratory of Protein Biochemistry and Protein Engineering3, 
Ghent University, Ghent, Belgium, B-9000 
Running head: α-Synuclein cross-linking in Lewy bodies 
Address correspondence to: Zoltan Nemes MD, PhD, 98 Nagyerdei krt., Debrecen, Hungary  
H-4012, +36-52431957, Fax: +36-52314989, E-mail: znemes@dote.hu 
 
The α-synuclein immunopositive and 
chaotrop-insoluble material from human 
brains with Lewy body pathology was analysed 
by mass spectrometry. From the proteinase K-
cleavable peripheral fraction of Lewy bodies, 
which was densely cross-linked by γ-Glutamyl-
ε-Lysine bonds  between HspB1 and ubiquitin 
in a pattern similar to neurofibrillary tangles, 
(Nemes et al. 2004, Faseb J. 18; 1135-7.) 53 
proteins were identified. In the core of Lewy 
bodies only α-synuclein was found and it 
contained a low amount of intra-molecular 
cross-links between Gln99 and Lys58. In vitro 
cross-linking of α-synuclein by 
transglutaminases 1, 2, 3 and 5 produced 
heterogeneous population of variably cross-
linked α-synucleins in solution, which inhibited 
the aggregation of the protein into amyloid. 
However, in the presence of 
phosphatidylserine-rich membranes and 
micromolar calcium concentrations, the cross-
linking by transglutaminase 1, 2 and 5 showed 
specificity towards the utilization of Gln99 and 
Lys58. As shown by Thioflavine T fluorescence 
monitoring, the formation of this cross-link 
accelerated the aggregation of native α-
synuclein. Chemical cross-linking of residue 58 
to 99 triggered amyloid formation, whereas 
such bonding of residue 99 to 10 was inhibitory.  
Our findings reveal the pivotal role of 
membrane attachment and transglutaminase-
mediated intre-molecular cross-linking for the 
propagative misfolding and aggregation of α-
synuclein. 
α-Synuclein is a widely expressed 
neuronal protein, which can form amyloid 
deposits under pathological conditions. The 
extracellularly deposited α-synuclein, or the 
central segment of it, is known as the “non-Aβ 
component” of amyloid and is involved in the 
formation of senile plaques in Alzheimer’s disease 
(AD).  
The intraneuronal aggregation of α-
synuclein leads to the formation of Lewy bodies. 
These inclusions were initially thought to 
hallmark the degenerating dopaminergic neurons 
in Parkinson’s disease: however, they are 
abundant in cortical neurons and basal ganglia in 
distinct neurodegenerative dementias, such as AD 
and Lewy body dementia (LBD) and are often 
found in neurons of elderly people without any 
clinical record of parkinsonism or dementia (1). 
The ultrastructure of a Lewy body reveals a 
compact amyloid core surrounded by a fuzzy halo 
that is vaguely abridged from the neuronal 
cytoplasm. Lewy bodies (LB) are strongly 
immunopositive for α-synuclein and ubiquitin. 
They may also contain many other components 
(such as synphillin-1, dorfin or parkin), which 
have not yet been investigated in detail (see (2) for 
references).  
 α-Synuclein is a small protein of 140 
amino acids and consists of an N-terminal lipid-
binding amphipathic domain, a C-terminal acidic 
tail and amyloid-forming repetitive sequences in 
between. α-Synuclein is almost unstructured as 
a monomer in aqueous solution, but 
undergoes a conformational change to an α-
helical structure upon association with 
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negatively charged membranes or β-pleated 
sheet conformation upon aggregation to amyloid 
(see (3) for references). Owing to its natively 
disordered conformation, the protein readily 
aggregates with itself and co-aggregates with 
other proteins, a property which may be necessary 
for LB formation and its cytopathic effects. Given 
that α-synuclein does not assemble into persistent 
aggregates under normal conditions of a living 
neuron, it is critical to identify triggers of 
propagative α-synuclein misfolding, as these may 
result in a complex pathological sequelae leading 
to LB formation and neuron loss.  
 Transglutaminases (TGs) are a family of 
proteins that catalyze the exchange of the γ-
(carbox)amido group with a different amine. If the 
amine is provided by the ε-amino group of a 
protein-bound lysine, TGs cross-link proteins via 
γ-glutamyl-ε-lysine (GGEL) isopeptide cross-
links, see (4) for references. Four of the nine 
human TGs, (TG1, 2, 3 and 5) are expressed in the 
brain (5,6). The most investigated TG2 is present 
in two splice variants, the shorter of which results 
from an intronic read-through and was shown to 
associate with Alzheimer’s neurons (7). A 
previous work from our laboratories identified α-
synuclein cross-linked via its Gln99 moiety to 
ubiquitin Lys48 in ubiquitylated intracellular 
aggregates from AD specimens (8). 
 Using an anti-GGEL antibody, two earlier 
reports showed the presence of GGEL cross-links 
in α-synuclein aggregates from Lewy bodies. 
However, the precise role and the manner of 
synuclein cross-linking, and its relevance to the 
pathogenic process has not been revealed (9,10). 
The in vitro and cellular models yielded 
conflicting conclusions; both a pro- and anti-
aggregation roles have been proposed (10-12) and 
also the lack of α-synuclein cross-linking in a 
transfection study was also reported (13).  
 A former in vitro analysis identified 
Gln79 and Lys80 as TG2-substrate residues (14) 
and a recent study (15) found that guinea pig TG2 
preferentially forms cross-links in soluble α-
synuclein between Gln79 and Lys60, Gln99 and 
Lys10, Gln109 and Lys32 or Lys34, and also 
Gln109 and Lys96. This study also analyzed the 
cross-linking of α-synuclein by soluble TG2 in a 
phosphatidyl-glycerol membrane bound state and 
found that the cross-linking pattern is dramatically 
affected by the membrane binding of the substrate 
inasmuch as it reduced the residues amenable for 
cross-linking to one, without identifying where 
this particular cross-link was.  
 In the present article, we demonstrate that 
a small fraction of α-synuclein in the aggregated 
core of LB is intra-molecularly cross-linked, and 
show by in vitro model experiments how LB can 
be nucleated by GGEL cross-links in a membrane-
dependent fashion. Our findings suggest that the 
formation of LB is triggered by TG-mediated 
intramolecular cross-linking, and this may be an 




Human specimens- DLB cases (2 males, 1 female, 
mean age 76±5 years), AD cases (3 females, mean 
age 83±7 years) and control cases (3 males, 2 
females mean age 78±4 years) were obtained from 
the Institute of Pathology, University of Debrecen 
Medical and Health Sciences Center. Control 
brain tissue was obtained from patients whose 
medical records had no hints of neurological or 
psychiatric problems. The diagnosis of probable 
LBD and AD was made according to clinical 
records and consensus neuropathologic criteria 
(16). Brain tissue was harvested 9―16 h post 
mortem with the permission of the Regional Board 
for Research Ethics. Tissue blocks were taken 
from the left hippocampus, and neocortex (medial 
frontal cortex).  
Isolation of α-synuclein immunoreactive, 
chaotrop-insoluble protein particles- Chaotrop-
insoluble material from tissue blocks was obtained 
by repeated extractions with Tripure reagent 
(Phenolic guanidine HSCN, Roche Applied 
Science, Mannheim, Germany) using a Teflon-
head homogenizer and repeated centrifugations at 
30,000 g. The insoluble material was boiled in 
Tris-Cl pH 8.0 containing 2% SDS and 100 mM 
ditiothreitol, washed in water and reacted with 
0.1M iodoacetamide for 1 h at room temperature, 
washed with water and pelleted as before.  
The remaining particulate material was washed 
with PBS containing 5 mM EDTA-Na and 
resuspended in 2 ml PBS with 1% BSA and 
shaken overnight with 1:50 diluted rabbit anti-α-
synuclein antiserum (Sigma, St. Louis, MO, USA) 
at 4°C. Particles were cleared from unbound 
antiserum by washing with PBS-BSA buffer and 
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then reacted with iron-microbead coupled goat 
anti-rabbit immunoglobulins (Miltenyi Biotech, 
Bergisch Gladbach, Germany). Immunoreactive 
particles were captured, washed and eluted on a 
Macs LS column (Miltenyi) according to the 
manufacturer’s protocol. Eluted particles were 
stripped of bound antibodies by two extractions 
with hot Tris-Cl pH 8.0 containing 2% SDS and 
100 mM dithiothreitol and washed with water. 
Ubiquitin affinity-separation was done exactly as 
published (8). 
Determination of the relative abundance of GGEL 
cross-links- The amount of amino acids was 
assessed from an aliquot of the samples by 
complete acid hydrolysis (6N HCl, 110oC 
overnight) followed by amino acid analysis using 
a Beckman 6300 amino acid analyzer. Total brain 
tissue proteins were purified after TriPure lysis 
and merging TriPure-soluble and insoluble 
fractions. Sample proteins were supplemented 
with approx. 0. 1 pmol GGEL (Sigma) as internal 
(light) standard, and subjected to limited acid 
hydrolysis (0.5 N trifluoroacetic acid (TFA) at 
95°C for 16 h), dried, then digested with 
proteinase K (Roche, 20 µg/ml in 10 mM HEPES-
Na pH 8.0 and 1mM CaCl2) in water containing 
20% H218O (Aldrich, St. Louis, MO, USA) at 
56°C overnight. After inactivating the protease at 
95°C, the peptides were further digested by the 
addition of a mixture of carboxypeptidase A, Y 
and leucine-aminopeptidase (all from Roche, 5 
µg/ml each at 37°C for 16 h), and the GGEL 
content was determined by derivatizing the 
samples with 9-fluorenylmethyl-succinimidyl 
carbonate, separated by HPLC on a C18 column 
and analyzed by LC/MS (Q-TRAP4000, Applied 
Biosystems, Foster City, CA, USA) monitoring of 
the ratio of masses at 719/721/723 atomic mass 
units as published (17). 
Digestion, enrichment and sequencing of LB and 
in vitro cross-linked α-synuclein- 20―30 µg of 
affinity-isolated particles from brain tissue were 
shaken overnight in 70% formic acid containing 
0.1% CNBr, dried in vacuum and digested first 
with 50U/µg bacterial alkaline phosphatase 
(Sigma type III) in 0.1M ammonium bicarbonate 
buffer (ABB) at 37°C for 60 min, then overnight 
with 1/20 weight modified trypsin (Roche). The 
undissolved particulate material was collected by 
centrifugation at 30,000 g. The supernatants were 
dried, dissolved in PBS containing 0.5% BSA and 
0.5% octyl-glycoside and incubated overnight 
with 20 µg mouse anti-GGEL immunoglobulin 
81D4 (Covalab, Lyon, France) at 4°C. 
Subsequently, 0.5 mg protein A Sepharose was 
added to the samples and washed twice with 
centrifugation and resuspension in PBS. Finally 
the pellets were suspended in 0.1% TFA to release 
the bound GGEL-peptides from the antibody and 
spun through a Microcon YM-10 membrane. In-
gel digestion of Coomassie-stained gel slices was 
preceded by a 20-min. wash with ABB in 50% 
acetonitrile and a 10-min. 75% acetonitrile wash. 
Then, 4 µg of modified trypsin (Roche) was added 
and proteolysis was carried out overnight at 37°C 
twice. In some experiment a third round of 
digestion with 2 µg Glu-C endoproteinase (Sigma) 
was applied. The peptide fragments were analyzed 
by LC/ESI/MS/MS using an Ultimate MicroLC 
system (Dionex-LC Packings, Sunnyvale, CA, 
USA) coupled to the Q-Trap tandem mass 
spectrometer. In some experiments samples were 
mixed with sinapinic acid, dried on steel source 
plates and analyzed on a MALDI TOF/TOF 4700 
instrument (Applied Biosystems). Read sequences 
were searched against the NCBI non-redundant 
database using the Mascot algorithm 
(www.matrixscience.com). Nonhuman and 
hypothetical proteins, keratins were ignored. 
Proteinase digestion of the proteinase-resistant 
LB fractions- The fraction of LB remaining after 
tryptic or proteinase K digestions was dissolved in 
100 µl 6M guanidine-HCl containing 1mg/ml egg 
albumin, heated at 95 °C for 5 min, desalted, and 
digested with 4 µg trypsin as above.  
Immunoelectron microscopy- Particulate material, 
occasionally digested with 10mg/ml Proteinase K 
overnight as above, was blocked with 10% normal 
swine serum in PBS for 30 min in suspension, 
then stained with rabbit anti-α-synuclein (1:200, 
Sigma). Primary antibodies were detected with 1 
nm gold-conjugated goat anti-rabbit 
immunoglobulins (1:50, Amersham, Amersham, 
England), fixed in 2% glutaraldehyde in PBS, and 
intensified using a silver enhancement kit 
(Amersham) After washing with ABB, particles 
were dried and resuspended in 1% uranyl-acetate 
in 70% ethanol and then embedded in Lowicryl. 
Ultrathin sections were cut (~70 nm) with a 
diamond knife, collected on copper mesh grids, 
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and viewed using a Hitachi 7100 electron 
microscope at 20,000x magnification. Adobe 
Photoshop (Adobe, San Jose, CA, USA) was used 
to adjust brightness and contrast, and to construct 
the final images.  
Cloning, Expression and Purification of 
Recombinant Proteins- α-synuclein cDNA was 
amplified from a human brain large-insert cDNA 
library (Clontech, Mountain View, CA, USA), and 
was ligated into pET-3b (Novagen, Darmstadt, 
Germany). Lys58Cys-Gln99Cys and Lys10Cys-
Gln99Cys double mutants were created by site-
directed mutagenesis using the QuickChange kit 
and protocol (Stratagene, La Jolla, CA. USA). α-
Synuclein cDNAs were expressed in BL21(DE3) 
E. coli and purified from the lysates according to 
Conway et al (18), with the exception that 
HiTrapQ columns (Amersham) were used instead 
of DEAE columns. TG1, 2, 3 and 5 were 
expressed in insect cells and purified as published 
(5,19-22).  
In vitro cross-linking experiments- Activity of the 
TG preparations was normalized to 0.005 
∆OD/min by the plated ELISA method of 
Slaughter et al(23). TG3 was activated by dispase 
as before (24). This was followed by the 
incubation of 4 µg (or 100 µg in high 
concentration experiments) α-synuclein with the 
TG of interest in 400 µl 50mM Tris-Cl pH 8.5, 
2mM DTT with or without 1mM CaCl2 for 30 min 
at 37°C. The products were either immediately 
digested with trypsin or analyzed by SDS-PAGE 
followed by immunoblotting with mouse anti-α-
synuclein antibody (Sigma), or separated by SDS-
PAGE, stained with Coomassie, and digested in-
gel with trypsin and desalted with PerfectPure C-
18 tips (Eppendorf, Hamburg, Germany).  
Preparation of Lipid Vesicles (LV) — Solution 
mixtures (55:15:30) of palmitoyl-oleyl-
phosphatidylcholine (PC), palmitoyl-oleyl-
phosphatidylserine (PS), and cholesterol, (all from 
Sigma) were made in chloroform/methanol (95:5). 
The solvent was evaporated and then resuspended 
by vortexing in 0.5 ml of a buffer containing 
50mM Tris-Cl (pH 8.0), 100mM NaCl, 3mM 
NaN3, 5 mM dithiothreitol, and 200 mM sucrose 
and dounced for 15 min through a 200 nm 
polycarbonate membrane using a LiposoFast 
pump (Sigma). Stock mixtures were made in 0.5 
ml and contained 50 µmol of total lipids. 
Protein-LV association assays — Mixtures 
contained 10 pmol protein and variable amounts 
of LV. Binding of proteins to LV was measured 
by spinning 20-40% of 0.5 ml mixtures of α-
synuclein and LV through a Microcon YM-100, or 
TG and LV through a Centrisart 300 kDa 
membrane and comparing the concentration of 
proteins in the ultrafiltrates to LV-free controls 
using the Bradford protein assay method. Free Ca 
ion concentrations at 1 mM were buffered with (5 
mM) Ca-citrate, 138 and 32 µM with Ca-
nitrilotriacetic acid and 2,3 µM with Ca-1,2-Bis(2-
amino-5-bromo-phenoxy)ethane-N,N,N’,N’-
tetraacetic acid (Calbiochem, Darmstadt, 
Germany), and calculated using MaxC program 
((25), http://www.stanford.edu/~cpatton/winmaxc32.exe ). The 
membrane fusion of LV preparations in calcium-
containing buffer was monitored by the 
measurement of light scattering (optical density) 
at 360 nm. A decrease of light scattering (resulting 
from vesicle membrane fusion) was less, than 
10% of the initial OD in protein-free buffer over 
24 hours at 37 ºC with any Ca buffer used and 
less, than 4% when 10 µg/ml α-synuclein and TG 
was added to the reaction mixtures, respectively. 
Cross-linking in the presence of LV— Mixtures 
contained 10 µmol LV lipids, 50 mM Tris-Cl pH 
8.0, 3 mM NaN3 and 5 mM DTT 0.1 M Sucrose 
and 4 µg α-synuclein and 5 m∆OD/min TG in 400 
µl volume. Cross-linking was initiated by the 
addition of 5 mM Ca-buffer, and then reaction 
mixtures were incubated for 16-24 hours at 37 °C. 
In some experiments 4 mM p-nitrophenylacetate 
was used as a TG substrate and hydrolysis was 
detected by photometry at 405 nm in a plate 
reader.  
Aggregation experiments- Lyophilized α-
synuclein was dissolved in 6 M guanidine-HCl to 
make a stock solution at 50 mg/ml. Guanidine-
HCl was removed and buffer switched to 50 mM 
Tris-Cl pH 7.6 , 5 mM ditiothreitol and either 1 
mM CaCl2 or 0.5 mM EDTA by passing through a 
Sephadex-25 column. 2 mg of α-synuclein 
solution was inoculated with 50 µg of control or 
treated synuclein in 2.8 ml volume and incubated 
at 37°C for 10 days. Inoculating α-synuclein 
samples were delipidized by solvent extraction. 
Thioflavine-T binding analysis of α-synuclein was 
performed by diluting 50 times a 20 µl aliquot of 
the sample solutions at each incubation time with 
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10 mM Tris (pH 8.0) and 10 µM ThT, 
respectively, and fluorescence was measured after 
mixing and standing for 20 min. at room 
temperature (22°C) by a M4 spectrofluorimeter 
(Zeiss, Göttingen, Germany). The excitation and 
emission wavelengths were 440 and 480 nm, 
respectively and bandwidths of 
excitation/emission lights were 8:8 nm.   
Cross-linking of Lys58Cys-Gln99Cys and 
Lys10Cys-Gln99Cys  mutant α-synucleins- Intra-
molecularly cross-linked proteins were made by 
adding 5 mM bis-maleimidoethane (Pierce, Bonn, 
Germany) to a 0.2 mg/ml solution of mutant α-
synuclein, freshly gel-filtered from DTT-
containing buffer in 50 mM Veronal-Na pH 6.5 
and incubating at room temp. for 4 hrs. Intra-
molecularly cross-linked proteins were purified by 
preparative SDS-PAGE and masses were verified 




Similar recovery of GGEL cross-links from brain 
tissue by ubiquitin and α-synuclein affinity 
isolations. Previously we developed a technique to 
isolate insoluble macro-polymeric protein 
particles from Alzheimer’s diseased brains using 
ubiqitin affinity-purification. Since the particles 
featured similar antigens to neurofibrillary tangles, 
we claimed that the ubiqitin immunopositive 
material may correspond to those. Here we 
applied a similar approach to Lewy Body 
Dementia using α-synuclein as bait. However, α-
synuclein is a component of different intra- and 
extracellular aggregates, such as senile plaques. 
Therefore we first compared Alzheimer’s diseased 
and LBD brain tissue with age-matched controls, 
using either anti-ubiquitin or anti-synuclein 
affinity methods to see if the isolated materials 
were similar and differently or specifically cross-
linked. 
GGEL content was measured using protease 
digestion, 18O-labeling and comparison to internal 
standard in mass analysis. The overall frequency 
of GGEL in brain cortex varied between 42±23 
/109 and 572±117 /109 amino acids in the 
specimens, where the age-matched not demented 
control was the least cross-linked, and 
Alzheimer’s parietal cortex was the most cross-
linked. Cross-linking of LBD specimens was 
consistently intermediate between the Alzheimer’s 
and the control group of samples. Statistically 
significant (p<0.05) differences between the LBD 
versus both control and Alzheimer’s groups were 
measured only in case of tissues from the cortex 
(Fig. 1A). Further on, hippocampal tissue 
specimens were used as cross-linking was the 
highest here in the case of LBD. During the 
chaotrop, detergent- and thiol-extractions 
97.2―98.1% of total amino acids and 
23.4―37.6% of GGEL were lost. Affinity-
isolation of the insoluble fractions with anti-
ubiquitin antibodies (applied in excess) pulled 
down 74―81%, whereas anti-α-synuclein 
antibodies recovered 55―63% of residual GGEL 
content from either sample. A repeated extraction 
with the same antisera recovered 1,2―1.6 % of 
the previous protein mass both in case of anti-
ubiquitin and anti-α-synuclein antibodies. Re-
extraction of proteins from DLB hippocampi 
using the other primary antibody yielded 
2.8―3.5% when anti-ubiquitin pre-cleared LB 
were probed with anti-α-synuclein, and 
13.8±6.5% when anti-synuclein isolation was 
followed by anti-ubiquitin (Fig 1B) 
These data indicate that the major fraction 
of the isolated particulate material must be double 
immunopositve for ubiquitin and α-synuclein and  
thus originates from intracellular deposits. 
Thereafter this material is referred to as LB.  
Protease-degradable and highly cross-linked part 
of Lewy bodies. The frequency of GGEL cross-
links of LB was 1122±261 / 106, as determined by 
rating the GGEL content released by proteinase K 
digestions to the amino acids liberated by total 
acid hydrolysis from the corresponding aliquots. 
When, in place of acidolysis, the amino acids were 
hydrolized by enzymatic catalysis (or a sequence 
of limited acid hydrolysis or CNBr cleavage 
followed by exhausting endo- and ectoproteinase 
digestions), the abundance of GGEL was 
significantly higher (3280±494 / 106) indicating 
that the bulk of the protein mass did not 
disintegrate to amino acid monomers, and that the 
digestion failed to release further material when 
fresh aliquots of proteinase K were added. The 
protease-susceptible fraction of LB contained 
43±5.2% of total LB amino acids and 92-95% of 
cross-links (Fig. 1C). These data showed that LB 
are inhomogeneous in terms of protease 
susceptibility and cross-linking.  
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Peripheral “halo” and dense “core” fractions of 
Lewy bodies can be revealed by immunoelectron 
microscopy. Ultrastructural analysis of the LB 
particles showed that whole particles consist of a 
dense central core and a loose, electron-lucid 
bulky external layer, which hereafter we refer to 
as the “halo” zone. The halo zone vanished and 
disappeared when LBs were digested with 
proteinase K. (Figure 2.).  
Immunogold labeling revealed the presence of α-
synuclein immuoreactivity in both LB 
compartments. Ubiquitin immunoreactivity was 
confined to the halo zone and was effectively 
removed by proteinase K digestion. This finding 
suggests that the inhomogenity of LBs in terms of 
composition and cross-links may rather result 
from a different composition of LB core and 
periphery rather than from the dispersion of a-
synuclein droplets within a mesh-work of variably 
cross-linked and diverse cellular proteins. 
Halo zone of LBs is built from various proteins. 
Proteomic analysis of tryptic peptides obtained 
from the proteinase-digestible halo of LB from 
DLB hippocampi was performed. Using ion-
exchange and reverse phase fractionation (″2D-
LC″) followed by tandem MS sequencing, the data 
allowed the identification of 53 proteins from 
tryptic LB peptides (Table 1.), 41 of which were 
identified by multiple unique peptides. Of the 53, 
47 proteins had no previously known association 
with LB. Functional class distribution of these 53 
proteins was 23% cytoskeletal or structural, 19% 
energy and metabolism, 6% intracellular 
trafficking or synaptic, 17% signaling or protein 
modification, 17% ubiquitin-proteasome system, 
stress response or chaperon, and 17% unknown or 
other. Expected proteins such as α-synuclein, 
ubiquitin and TG2 were identified in our 
proteomic screen, confirming the ability of this 
approach to identify LB-associated proteins. 
Cross-linked proteins in LB halo zone. Using 
affinity-separation for the GGEL isopeptide link, 
seven cross-linked sequences were identified from 
the protease-susceptible fraction of LB (Table 2.). 
These sequences comprised ubiquitin Lys29 and 
Lys48, parkin Lys49 and HspB1 Gln31 and 
Gln190 and also α-synuclein Gln99. The most 
abundant of these were the ubiquitin Lys29 - 
HSPB1 Gln31 cross-bridges. Though a random 
cross-linking between substrate Lysines and 
Glutamines would predict the presence of HspB1 
Gln31 – ubiquitin Lys48 and also HspB1 Gln31 – 
parkin Lys49 cross-links, such peptide pairs were 
not found, similar to previous works with AD 
specimens (8). 
Proteinase K resistant LB core. The residual 
fraction of LBs after proteinase K digestion made 
up 57.1±3.7% of total LB amino acid mass. This 
material was completely soluble in chaotropic 
salts, such as guanidine hydrochloride and 
guanidine isothiocyanate, i.e., agents used to 
separate LBs from unpolymerized cellular 
proteins. This particulate material showed no 
apparent immunoreactivity to either ubiquitin or 
GGEL isopeptide bonds (not shown), but was 
strongly immunopositive for α-synuclein (Fig. 2). 
Electron density of the protease-resistant material 
was similar to that of LB cores and lacked the 
electron-lucid halo. The strong intermolecular 
interaction between the LB core α-synuclein 
molecules was suspended by chaotrop lysis and 
neutralization through mixing with an indifferent 
protein. Mass sequencing of LB core proteins 
identified solely α-synuclein. This apparent 
contradiction that α-synuclein aggregates were 
first not dissolved by chaotrpopic salts unless the 
halo was digested away might be explained by 
wrapping of α-synuclein amyloid (the core) into a 
bag of loosely packed, though densely cross-
linked, protein meshwork.  
GGEL cross-links in LB core. The frequency of 
GGEL cross-links in proteinase K-resistant LB 
fractions was 188±11 / 106 amino acids (Fig. 1.). 
As this fraction was built from virtually pure α-
synuclein protein, this frequency corresponds to 1 
cross-link in ~500 Lysines, or 1 cross-link for ~40 
α-synuclein molecules. Sequencing of cross-
linked tryptic peptides from LB core proteins 
showed that the cross-link was positioned between 
Lys58 and Gln99 (Fig 3A). MALDI mass analysis 
of α-synuclein from LB and sequences obtained 
from peptides with missed cleavages indicated 
that cross-links may connect residues within one 
α-synuclein sequence (Fig 3B). 
Cross-linking of α-synuclein by soluble  
transglutaminases in vitro. Human TG1, 2, 3 and 
5 were expressed in insect cells and were reacted 
with α-synuclein to analyze substrate specificity 
and comparison with cross-linking patterns seen in 
LB. All the enzymes resulted in a promiscuous 
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and apparently random utilization of most α-
synuclein Gln and Lys residues, with exceptions 
for Gln 134, 62 and Gln 24 and Lys 12, 22, 45, 60 
and 95, which were not used (Fig. 4.). This 
promiscuity of residue utilization corresponds to a  
randomly coiling, intrinsically disordered 
conformation of α-synuclein in solution (26). 
High α-synuclein concentrations yielded a higher 
amount of inter-molecular cross-links, which 
showed a poorly separating mixture of dimers and 
higher molecular weight oligomers, whereas intra-
molecular cross-linking created a dispersion of α-
synuclein mobility below the band of the native α-
synuclein on SDS-PAGE (Fig. 4.). Cross-linked 
residues were identified by sequencing in-gel 
trypsinized bands. Remarkably, only the first 
lysines were reactive from the X-Lys-Thr-Lys-X 
repeat tracts and Gln 62 was not accessible for 
cross-linking for either of the TGs.  
α-Synuclein and TG binding to membranes – 
In order to simulate biological conditions, the 
interaction of α-synuclein with lipid membranes 
was analyzed. Previous reports using 1:1 lipid 
mixtures of phosphatidylserine (PS) and 
phosphatidylcholine (PC) found a large variability 
in binding capacities ranging from 185 to 2000 
lipid molecules per bound α-synuclein (27,28). 
The dispersion of binding strengths might have 
resulted from different experimental conditions 
and variable membrane fluidity at ambient 
temperatures. We compared the binding of α-
synuclein to LV with fixed (15%) PS content at 
room temperature (22 °C) and 37 °C. As 
compared to room temperature, α-Synuclein 
binding was found to increase largely at 37 °C. 
Remarkably, heating LV - α-synuclein mixtures 
briefly to 37°C maximized binding even after 
cooling back to lower temperatures. This indicated 
that membrane fluidity is needed to anneal 
interacting PS molecules below the adhering 
protein (Fig 5/A).  
When membrane fluidity was assured by the 
addition of cholesterol and incubation at 37 °C, 
approx. 26 exposed PS molecules were sufficient 
to bind an α-synuclein. Next, we studied the effect 
of calcium ions on binding of α-synuclein to LV. 
The addition of Ca ions to the medium increased 
the affinity of α-synuclein to LV and reduced the 
number of required PS molecules to bind an α-
synuclein to ~11 at 1 mM Ca and ~15 at 2.3 µM 
free Ca (Fig 5/B).  
Next, we studied the binding of TGs to LV 
and the effect of membrane binding on enzyme 
activity. In the absence of Ca ions, LV did not 
show detectable binding to either TG, except for 
TG1, which is bound to membranes through fatty 
acylation (29). The addition of (buffered) Calcium 
ions, however, lead to the adsorption of  TG2 and 
TG5, but not TG3, onto LV (fig5/C) and resulted 
in the appearance of latent TG activity even at Ca 
concentrations, which were by two magnitudes of 
order below the free calcium requirements 
typically used and required by soluble TGs (Fig 
5/D).  
Cross-linking of α-synuclein in the presence of 
membranes. The addition of LV radically 
interfered with the residue selectivity of TG1 and 
restricted the promiscuous utilization of 
glutamines and lysines to intra-molecular cross-
linking between Gln99 and Lys58. Under 
conditions, when α-synuclein was fully adsorbed 
to membranes and free calcium concentration was 
high enough to ascertain full TG activity (1mM), 
the presence of LV also restricted the residue 
utilization of TG2 (Fig. 6.), as well as that of TG3 
and TG5 (mass data not shown). Intra-molecular 
cross-linking between α-synuclein Lys58 and 
Gln99 was abundant, but cross-links between 
Gln109 and Lys10, Gln109 and Lys58, Gln99 and 
Lys10 were also formed. Only one intra-molecular 
cross-link was formed per α-synuclein, in 
agreement with previous findings (15).  
Cross-linking of α-synuclein by LV-associated 
TGs. We tested if the Ca-dependent binding of 
TG2 and TG5 could restrict residue utilization 
similarly to membrane-binding of TG1 through 
fatty acylation. Whereas cross-linking at 32 µM 
free Ca generated multiple cross-linked products, 
similar to 1 mM Ca, at 2.3  µm free Ca, TG2 and 
TG5 created solely Gln99-Lys58 cross-links, 
alternatively bonded products were not detected 
(Fig. 7.). This suggests that product heterogeneity 
is not excluded only by the membrane adsoprtion 
(and possibly acquiring a membrane-bound helical 
configuration) of α-synuclein if active TGs can 
access its exposed Gln and Lys residues from 
many directions. Only if the activating effect of 
the LV membrane, and probably membrane-
presented Ca ions restrict TG activity to the plane 
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of the membrane surface will soluble TGs cross-
link as if they were fixed to the membrane by a 
lipid anchor. 
Effects of cross-linking on α-synuclein 
aggregation to amyloid. The rate of amyloid 
formation, i e., propagative β-pleated sheet 
forming aggregation process, was assayed by 
measuring the increase of fluorescence quantum 
efficiency of Thioflavine T dye in the presence of 
a minor part of α-synuclein products, which were 
cross-linked by TG. As the frequency of GGEL 
isopeptide cross-links was approximately 1 cross-
link in 40 α-synuclein molecules of LB core, TG 
modified synuclein was added to a 40-fold excess 
of native α-synuclein freshly dialyzed from 6 M 
guanidine-HCl.  
The addition of α-synuclein cross-linked 
by soluble TGs strongly inhibited α-synuclein 
aggregation, in agreement with previous findings 
(12,15,30). 
 The addition of Lys58-Gln99 intra-
molecularly cross-linked α-synuclein resulted in 
an earlier appearance of the aggregation signal, 
which was not affected by chaotrop interventions 
(boiling, guanidine-HCl) of the cross-linked 
proteins (Fig. 8/A). 
Seeding and blocking effects of chemical cross-
linking depending on cross-link position. Wild 
type α-synuclein contains no cysteins, thus 
introduction of two cysteins to replace TG-
reactive Gln and Lys residues offered a simple 
model to replace transglutamination and obtain an 
intra-molecularly cross-linked protein. Though the 
formation of intra-molecular disulfide bridges is a 
spontaneous process in a slightly oxidizing milieu, 
oxidized Lys58Cys-Gln99Cys α-synuclein did not 
enhance amyloid formation, possibly due to 
disulfide exchange and formation of inter-α-
synuclein disulfide bridges. Therefore the cysteins 
of mutant α-synuclein were cross-linked 
chemically through a short bis-maleimidoethane 
spacer, which does not isomerise in solution and 
could by purified by SDS-PAGE under reducing 
conditions. The addition of the 58-99 chemically 
cross-linked mutant enhanced α-synuclein 
aggregation into amyloid even at a 1:400 ratio to 
wild type synuclein. This effect was also inhibited 
by the addition of randomly TG2-cross-linked α-
synuclein. The similarly cross-linked Lys10Cys-
Gln99Cys α-synuclein blocked aggregate growth 
in a dose-dependent manner. Remarkably, the 
addition of this latter product decreased peak 
fluorescence, whereas the addition of 58-99 
bonded synuclein accelerated aggregation. We 
tested if the pro- or contra-aggregation effect was 
dominant over the other. The addition of both 
cross-linked isomers showed that the seeding 
effect of 58-99 was detectable also in the presence 
of the blocking 10-99 or soluble TG-treated α-




 The key event of Lewy Body formation is 
the appearance of a specific and propagating α-
synuclein conformation, when this natively 
unfolded protein acquires a structure that recruits 
other molecules to stick to the end of the proto-
fibril by forming β-pleated sheets between its 
repeat domains. Such amyloid-forming chain 
reactions are common in the extracellular 
compartment; though apart from prions, inside the 
cytoplasm α-synuclein is the only known wild 
type human protein, which behaves like that. 
Since the abundance of α-synuclein is not too high 
and other sticky proteins (such as heat shock 
proteins) can block the process (31), the initial 
formation of LB requires some kind of catalytic 
effect or loss of blocking or clearance mechanisms 
(32).  
Here LB were found to be first insoluble 
in chaotropic agents which are capable of 
disrupting non-covalent and disulfide bond 
interactions, but amenable to proteinase attack. In 
the α-synuclein amyloid core of LB, the cohesion 
of the proteins must have relied on homophile 
secondary interactions, which could not have 
survived the disruption and lysis by chaotrop salts 
applied during the isolation process - unless a 
cross-linked protein bag protected the proteins 
from diffusing away from one another. After this 
surrounding meshwork was digested away, the 
amyloid became readily soluble in chaotropic 
salts. This suggests that α-synuclein first may 
aggregate with itself, form amyloid that grows 
(“one-dimensional crystal”) as long as it can 
remain hidden from different proteins such as 
chaperones and ubiquitinating enzymes, which 
deposit onto the surface of amyloid as a 
surrounding and cross-linked layer afterwards. 
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 Previous data from our laboratories 
revealed a similar pattern for the covalent cross-
linking of the outer sheath of ubiquitin-
immunopositive insoluble aggregates from 
Alzheimer’s diseased brains and age-matched 
controls (8). These were regarded as 
neurofibrillary tangles, although may have been a 
mixture of LBs, tangles and possibly other 
aggregates (such as granulo-vacuoles, Hirano-
bodies), since ubiquitin and α-synuclein are 
ubiquitous components in several types of 
intramolecular inclusions. The restricted number 
of cross-linked sequences indicated that covalent 
isopeptide cross-linking targets generic, 
aggregated sequence-independent proteins, a 
finding largely corroborated by the current data. It 
is also noteworthy to mention that the proteomic 
analysis of Alzheimer’s neurofibrillary tangles 
identified a remarkably similar set of proteins to 
the ones found in the LB halo (33), which again 
suggests unspecific cellular response pathways to 
protein aggregation.   
 The role of TG-mediated cross-linking in 
the aggregation of α-synuclein has intrigued 
researchers since cross-links were detected in LBs 
by anti-GGEL immunohistochemistry and 
immunoblotting techniques (9,10,14,34). The 
overexpression of TG2 favored α-synuclein 
aggregation in cell cultures (10), nevertheless, a 
direct and unregulated crosslinking of α-synuclein 
blocked aggregation (12,15,30). This apparent 
conflict is reconciled and clarified by our findings, 
which show that α-synuclein from LB core 
contains sub-stochiometic amounts of Lys58-
Gln99 cross-links between residues of a single 
primary sequence and thus form a hairpin loop 
within the molecule. The abundance of 
transglutaminated α-synuclein is less than 1 
crosslink in 40 α-synucleins. This low rate of 
cross-linking is unlikely to deplete cellular α-
synuclein pools, as suggested in (9). Moreover, 
such infrequent cross-linking may have modest 
impact on α-synuclein solubility and persistence, 
once it has aggregated into amyloid.  
Our findings suggest that low amounts of 
Gln99-Lys58 cross-linked synuclein might act as 
inoculating seed for amyloid-type aggregation of 
unstructured soluble α-synuclein chains. Intra-
molecular cross-linking of α-synuclein trigger the 
amyloid fibril formation of native α-synuclein, 
whereas heterogenic mixtures of differently cross-
linked proteins block it, as shown also by previous 
reports (12,15,30). This observation is in accord 
with recent models of α-synuclein fibrillarization, 
which predicted that the core region of the protein 
(approx. 35-105 positions) stack to one another as 
hairpin-like folds of five short (7-9 residue long) 
β-pleated sheet forming tracts, where Lys58 and 
Gln99 would be located to the flexible loops 
connecting these sheets (35). Even the 61―95 α-
synuclein sequence or shorter tracts of it may form 
powerful β-amyloid aggregates (36). As we 
showed here with chemically cross-linked α-
synuclein, cross-linking variable or different 
residues can mismatch and disrupt annealing, 
whereas a precise hairpin cross-linking of the 
randomly coiling backbone can accelerate 
matching and assembly of complementary 
hydrogen bonding partners within and between the 
loops.  
 The cytoplasmic surface of membranes is 
a unique micro-compartment for many catalytic 
processes. The calcium ions coming from 
extracellular or vesicular pools are accumulated 
by the phosphatidylserine-rich inner membrane 
surface and thus the cytosolic face of membranes 
serves as calcium stores which can promptly 
regulate calcium-dependent enzymes as 
exemplified by the processes of synaptic vesicle 
trafficking, docking and fusion in presynaptic 
nerve termini, or dendritic spine movements in 
glutamatergic synapses (37,38). α-Synuclein is a 
synaptic vesicle-associated protein that variably 
associates to, and dissociates from, the outer 
surface of vesicles, a process presumably 
regulated by the master regulator of synaptic 
vesicle turnover, i.e. calcium signaling. 
Transglutaminases need to bind multiple calcium 
ions for activation (39), and attain active 
conformation at calcium concentrations that do 
not occur in the gross cytoplasm of living cells 
elsewhere than in sub-membranous calcium pools, 
and even there, only for microseconds.  
In our model the accumulation of calcium 
ions by phosphatidylserine-rich membranes 
lowered the calcium ion requirements for soluble 
TGs by magnitudes or order, possibly both by 
calcium and substrate presentation effects. This 
effect has been noted earlier for TG1 (22), but not 
for membrane-bound soluble TGs. This indicates 
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that the effect of membrane coordination is not 
unique to TG1, but also affects soluble cytosolic 
TG isoenzymes, the activities of which were thus 
far thought to be latent under the low calcium 
conditions occurring in living cells (40). 
Though TG2 is held to be the most 
expressed TG in neurons, this belief is largely due 
to the fact that the other TG congeners have not 
yet been investigated in detail and redundantly 
expressed TGs may exert overlapping activities 
with TG2 (4). The binding of both α-synuclein 
and transglutaminase in the presence of calcium 
ions were sufficient to direct the broad residue 
specificity of TG1, TG2 and TG5 to the same 
substrate residues in α-synuclein and block 
alternative sites for cross-linking. The orienting 
effect of membrane attachment might explain why 
TG2, an enzyme ubiquitously present in cells both 
in cytosolic and acylated, membrane-attached 
forms (41,42), favored α-synuclein inclusion 
formation in cell culture (10), but blocked 
aggregation in vitro (30).  
 Our findings reveal that intramolecular 
cross-linking by membrane-bound trans-
glutaminase activity promotes the nucleation of α-
synuclein amyloid (proto)fibrils, and the cross-
linking of ubiquitin and HspB1 on the surface of 
these inclusions is a generic secondary process 
that encapsulates Lewy bodies in vivo (Fig. 10.). 
What the cell may gain from the formation of 
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Fig. 1. γ-Glutamyl-ε-Lysine cross-links in brain fractions accumulate in α-synuclein immunopositive 
chaotrop-insoluble inclusions/Lewy bodies. The relative abundance of GGEL was determined by enzymatic 
hydrolysis of sample proteins in 18O-water and comparison to light internal GGEL standard by mass 
spectrometry. GGEL was related to total amino acid content.  (A) GGEL accumulation associates with 
regions affected by degenerative changes in human brain specimen affected by Lewy body dementia (LBD), 
Alzheimer’s Disease (AD) or in age-matched controls (CTRL). Over 50% of total tissue GGEL content was 
recovered by either anti-ubiquitin or anti-α-synuclein affinity isolation from chaotrop-, detergent- and thiol 
insoluble brain proteins (B), indicating that most of the cross-linked inclusions expose both antigens in AD 
and LBD. Lewy bodies were exhaustively digested with Proteinase K. Residual proteins remaining after 
digestions were dissolved in guanidine-HCl and co-precipitated with a different protein (egg albumin) to 
disrupt β-sheet amyloid arrays between proteins. The GGEL density in Proteinase K resistant fractions is by 
an order of magnitude lower than in the proteinase-digestible part (C). Bars represent the means of duplicate 
determinations from 3 different donors. Asterisks and hash marks indicate significant (p<0.05) differences 
from the corresponding controls and AD samples, respectively.  
 
Fig. 2. The halo of Lewy bodies is fuzzy and contains ubiquitin, whereas the core consists of compacted α-
synuclein. Transmission electron microscopic images of Lewy bodies without (A) and after Proteinase K 
digestion (B). Lewy bodies were affinity-isolated with anti-α-synuclein antiserum from brain cortex and 
immunostained with anti-ubiquitin and anti-synuclein primary and gold-particle-labeled secondary antibodies 
and counterstained with Uranyl-acetate before embedding. (Bar= 0.25 µm).  
 
Fig. 3. α-Synuclein from Lewy bodies is internally cross-linked between Gln99 and Lys 58. Ion 
nomenclature and Q-Trap mass spectrum of the trypic peptide pair with γ-Glutamyl-ε-Lysine cross-link 
between Gln 99 and Lys 58 of α-synuclein (A). Only the fragment ion masses harboring the cross-link are 
labeled. * marks fragments 18 mass units below the expected mass (water loss). B,  MALDI mass analysis of 
trypsin-digested α-synuclein features a peak of 5546 Da (monoisotopic, M+H+) comprising internally cross-
linked residues 49 to 102 of α−synuclein, which can not form from two inter-molecularly cross-linked 
proteins. The peak at 5564 Da is a mixture of multiple isobaric sequences resulting from Gln-deamidation of 
the (not cross-linked) 49-102 α-synuclein peptide and hydrolytic cleavage of the cross-linked same sequence 
between Lys58 and Gln99 residues.  
 
 
Fig. 4. Transglutaminase1, 2, 3 and 5 elicit a promiscuous cross-linking of α-synuclein in solution, as 
evidenced by the formation of cross-linked oligomers not fully separated by size on SDS-PAGE (A). 250 
µg/ml α-synuclein was exhaustively reacted with recombinant human TGs in solution. Electrophoretic 
separation of 1 µg/ lane transglutaminase-modified α-synuclein was visualized by immunoblotting.  Low (10 
µg/ml) α-synuclein concentrations favor intra-molecular cross-linking, as shown by the dispersion of α-
synuclein electrophoretic mobility towards faster moving products (B) and multiple cross-linked Glutamine 
and Lysine residues identified in the transglutaminated products by mass sequencing after digestion with 
trypsin and Glu-C endoprotease (C). Mass peaks were sequenced by ESI/MS/MS and shown in a 
deconvoluted format. Only transglutaminated product peaks are labeled. The cross-linked residues are listed 
in (D). Residues utilized for cross-linking are superscripted, the neglected ones are shown in subscript. Single 
letter code for amino acids is used.  
 
Fig. 5. Binding of α-synuclein and transglutaminases to lipid vesicles (LV). 10 pmol α-synuclein was added 
to varying amount of LV from 15% phosphatidylserine, 55% phosphatidylcholine and 30% cholesterol at 
room temperature (full dots) and 37 °C (hollow dots). The not membrane-bound fraction of protein was 
measured from centrifugal ultrafiltrate. A, Warming LV / α-synuclein mixtures to 37 °C (triangles) results in 
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increased protein binding, which is preserved at the lower temperature thereafter. This phenomenon indicates 
that membrane fluidity is needed to fit interacting PS and α-synuclein residues together. B, Calcium ions 
increase α-synuclein association to PS-containing LV. The ratio of synuclein / PS (mol/mol) is plotted., error 
bars show 95% confidence intervals. C, binding of TG1 to LV is independent of calcium concentration, 
whereas TG2 and TG5 associate with LV in a calcium ion dependent manner. In the presence of LV, 
micromolar calcium ion concentrations elicit detectable TG activation for TG2 and TG5, (D), however, in 
solution these concentrations do not activate them (inset in panel D). The patterning of columns showing 
different free Ca concentrations is the same as on panel C. TG1 is fully active at the lowest tested calcium 
concentration, whereas TG3 does not associate with LV neither is its activity affected by LV. TG activity 
was measured by assaying p-Nitrophenyl-acetate hydrolysis by photometry. Points indicate means of 5 
independent assays.  
 
Fig. 6. The addition of LV restricts substrate residue utilization in α-synuclein for TGs. α-synuclein was 
cross-linked by transglutaminases in the presence of LV and calcium buffers. (A) 2 µg α-synuclein per lane 
was detected by immunoblotting. In case of TG1, which is membrane-bound by default, only Gln 99 and Lys 
58 were utilized. The orienting effect of acidic membranes in the presence of 1 mM calcium concentration 
reduced the complexity of α-synuclein products generated by TG2, TG3 and TG5, as shown by the 
separation of discrete bands on SDS-PAGE and mass fingerprint of TG treated α-synuclein fragmented in-
gel with CNBr and trypsin and analyzed by LC-ESI-MS/MS (B). Mass peaks are shown in deconvoluted 
format. TG3 and TG5 produced fragments corresponding to the pattern of TG2 and are therefore not shown. 
Under these conditions a-synuclein is fully membrane-bound, whereas TG2 is present as active soluble and 
membrane-bound state.  
 
Fig. 7. The membrane-association of α-synuclein and TGs direct residue specificity to Gln 99-Lys 58 cross-
linking and eliminates the production of variably cross-linked α-synuclein products. Micromolar calcium 
levels are locally accumulated on the surface of PS-containing LV and activate TG2 and TG5 in a 
membrane-dependent manner. Under low calcium conditions the soluble TG is not activated. Contrasted to 
32 µM Ca, at 2,3 µM Ca concentrations, TG2 and TG5 shows specificity towards utilization of Gln99 and 
Lys58 for cross-linking. 1 µg α-synuclein per lane was detected by SDS-PAGE immunoblotting. Cross-
linked residue positions were detected as on Fig. 6.  
 
Fig. 8. Effect of cross-linked α-synuclein on amyloid formation. The aggregation of unmodified α-synuclein 
was monitored by recording Thioflavin T (ThT) fluorescence after addition of 2.5% α-synuclein incubated 
exhaustively with TGs. (A) Heterogenously cross-linked α-synuclein produced by TG2 in solution (●) or in 
the presence of LV and 32 µM Ca (▲) inhibits aggregation to amyloid, whereas homogeneously cross-linked 
α-synuclein produced by either TG1 (♦), or TG2 on LV at 2.3 µM Ca (○) does not block fibril assembly. 
Inset in B: Lys58Cys-Gln99Cys (lane 1) and Lys10Cys-Gln99Cys (lane 3) α-synuclein mutants were cross-
linked between their two cystein residues (lane 2: 58-99, lane 4: 10-99 cross-linked) by bis-maleimidoethane. 
The site of cross-linking resulted in a different electrophoretic mobility of the isomeric products on 4-20% 
SDS-PAGE gel. The 58-99 cross-linked protein shows seeding effect and accelerates the assembly of α-
synuclein into amyloid (B), whereas the 10-99 cross-linked protein blocks amyloid growth in a dose-
dependent manner (C). These effects are detectable and dose-dependent in the presence of the other type of 
cross-linked product (D). Points show the means of a representative experiment performed in triplicates. 
 
Fig. 9. Scheme for LB biogenesis. The propagative β-sheet hairpin formation is favored by restricting α-
synuclein random coiling with membrane association and intra-molecular cross-linking. The growth of fibrils 
can proceed as long as other proteins, such as chaperones clog the growing ends. Attachment of 
(poly)ubiquitin chains, and chaperones (such as HspB1) block amyloid expansion. A covalent meshwork by 
cross-linking small heat shock proteins with ubiquitin encapsulates the unclearable aggregate.  
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Table 1. Tryptic peptides identified by ESI/MS/MS from the peripheral (directly digestible) zone of Lewy 
bodies. “Multiple entries” indicates that the sequences are common in many related sequences belonging to 
redundant entries, splice variants or close homologues of the same type of protein. 
 
No. Protein name     FASTA accession number 
1. Actin, cytoplasmic       Multiple entries 
2. Alpha crystallin B chain      P23927 
3. Alpha-internexin      Q16352 
4. Alpha-synuclein      P37840 
5. Aldolase 1, A isoform      P05064 
6. Aspartate aminotransferase     P05202 
7. Ca/calmodulin-dep. protein kinase type II α chain Q9UQM7 
8. Calmodulin        P62204 
9. Carbonic anhydrase II      P00920 
10. Cofilin 1       P18760  
11. Dihydropyrimidinase related protein-2    O08553 
12. EH-domain containing 1     Multiple entries 
13. Elongation factor 1-alpha 1     P10126 
14. Endophilin-3-interacting protein     Q9BQI5 
15. Enolase 2, gamma neuronal      P17183 
16. FK506-binding protein 1A      P26883 
17. Glutathione S-transferase P1     P19157 
18. Glyceraldehyde-3-phosphate dehydrogenase  P16858 
19. Heat shock protein Beta-1 (HSP 27)   P04792 
20. Heat shock 70kD protein 8      P63017 
21. Heat shock cognate 71 kDa protein    P11142 
22. Malate dehydrogenase, cytoplasmic    P08249 
23. Manganese superoxide dismutase     P09671 
24. Myc box-dependent-interacting protein 1   O00499 
25. N-myc downstream regulated 1    Q62433 
26. Neurofilament heavy polypeptide    P12036 
27. Neurofilament light polypeptide    P07196 
28. Neurofilament medium polypeptide    P07197 
29. Nucleoside diphosphate kinase B     Q01768 
30. Peptidyl-prolyl cis-trans isomerase A    P17742 
31. Peroxiredoxin 5       P99029 
32. Protein CGI-38 homolog      Q9CRB6 
33. Protein-glutamine gamma-glutamyltransferase 2 (TG2) P21980 
34. Pyruvate kinase, isozyme M2     P52480 
35. Rab GDP dissociation inhibitor alpha   P50396 
36. Ras related protein Rab-10     P61027  
37. Septin-2        P42208 
38. Septin-7       O55131 
39. Sirtuin 2        Q8VDQ8  
40. Spectrin, β-chain, brain 1     Q01082 
41. Synapsin IIa       Q92777 
42. Parkin        Multiple entries 
43. Tau        Multiple entries 
44. Tubulin alpha       Multiple entries 
45. Tubulin beta 2       P68372 
46. Tubulin beta 4       Q62364  
47. Ubc protein        Q922B0 
48. Ubiquitin       Multiple entries 
49. Ubiquitin carboxyl-terminal hydrolase isozyme L1 P09936 
50. Visinin-like 3       P62748 
51. 14-3-3 zeta/delta       P63101 
52. 14-3-3 epsilon       P62259  
53. 26S proteasome complex subunit DSS1   P60896   
 16
Table II.  Sequence assignments of cross-linked tryptic peptide pairs from the complex, protease-digestible 
halo and the α-synuclein amyloid containing core of Lewy bodies. Cross-linked peptides were affinity-
isolated from tryptic digests and sequenced using LC/MS/MS. Bolded residues are forming the γ-Glutamyl-ε-
Lysine isopeptide cross-links. A sequence deconvolution of pair 8 is shown in Figure 3. 
 
# Mass  Sequence  Protein Sequence position 
 
LB halo:  
 
1. 1244.3 D-E-L-G-K   α-synuclein  98-102 
   A-K-L-Q-D-K   ubiquitin  28- 32 
 
2. 1625.9 A-E-L-G-G-P-E-A-A-K HspB1  189-198 
   A-K-L-Q-D-K   ubiquitin  28- 32 
 
3. 1847.6 L-F-D-E-A-F-G-L-P-R HspB1   28- 37 
       A-K-L-Q-D-K  ubiquitin  28- 32 
 
4. 1873.8  D-E-L-G-K  α-synuclein  98-102 
      V-I-F-A-G-K-Q-L-E-D-G-R parkin  43-54 
 
5. 1888.2 D-E-L-G-K   α-synuclein  98-102 
     L-I-F-A-G-K-Q-L-E-D-G-R  ubiquitin  43-54 
 
6. 1955.1 A-E-L-G-G-P-E-A-A-K HspB1  189-198 
    V-I-F-A-G-K-Q-L-E-D-G-R  parkin  43-54 
 
7. 2270.9 A-E-L-G-G-P-E-A-A-K HspB1  189-198 




8.  2006.2     D-E-L-G-K  α-synuclein  98-102 
E-G-V-V-H-G-V-A-T-V-A-E-K-T-K   α-synuclein  45-60  
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FIGURE 9. (Nemes & al.) 
 
 
 
 
